Norway Savings Bank Buys 873 Shares of Becton, Dickinson and Company $BDX

Norway Savings Bank lifted its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 16.6% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,121 shares of the medical instruments supplier’s stock after purchasing an additional 873 shares during the quarter. Norway Savings Bank’s holdings in Becton, Dickinson and Company were worth $1,054,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of BDX. Brighton Jones LLC raised its position in Becton, Dickinson and Company by 98.2% in the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock valued at $401,000 after buying an additional 877 shares during the last quarter. Hara Capital LLC increased its position in shares of Becton, Dickinson and Company by 26.4% during the 4th quarter. Hara Capital LLC now owns 335 shares of the medical instruments supplier’s stock worth $76,000 after purchasing an additional 70 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Becton, Dickinson and Company by 3.8% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,701 shares of the medical instruments supplier’s stock worth $5,377,000 after purchasing an additional 861 shares during the last quarter. Numerai GP LLC acquired a new position in shares of Becton, Dickinson and Company during the 4th quarter worth approximately $471,000. Finally, Nomura Holdings Inc. increased its position in shares of Becton, Dickinson and Company by 357.2% during the 4th quarter. Nomura Holdings Inc. now owns 13,854 shares of the medical instruments supplier’s stock worth $3,143,000 after purchasing an additional 10,824 shares during the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently commented on the company. Citigroup downgraded Becton, Dickinson and Company from a “strong-buy” rating to a “hold” rating and reduced their target price for the stock from $217.00 to $185.00 in a research note on Thursday, May 22nd. Wells Fargo & Company lifted their target price on Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an “equal weight” rating in a research note on Friday, August 8th. Piper Sandler reiterated a “neutral” rating and set a $200.00 target price (up from $185.00) on shares of Becton, Dickinson and Company in a research note on Friday, August 8th. Morgan Stanley lifted their target price on Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an “overweight” rating in a research note on Monday, August 11th. Finally, Wall Street Zen upgraded Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Saturday, August 9th. Four research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $211.44.

Insiders Place Their Bets

In other news, EVP Michael David Garrison sold 1,185 shares of the business’s stock in a transaction on Friday, July 18th. The stock was sold at an average price of $180.29, for a total transaction of $213,643.65. Following the completion of the transaction, the executive vice president owned 4,887 shares of the company’s stock, valued at approximately $881,077.23. The trade was a 19.52% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Claire Fraser sold 917 shares of the business’s stock in a transaction on Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total value of $171,937.50. Following the transaction, the director directly owned 22,226 shares of the company’s stock, valued at $4,167,375. This trade represents a 3.96% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 2,965 shares of company stock valued at $551,536 in the last three months. 0.36% of the stock is owned by insiders.

Becton, Dickinson and Company Price Performance

Shares of NYSE BDX opened at $187.23 on Friday. The stock has a market capitalization of $53.66 billion, a PE ratio of 33.67, a P/E/G ratio of 1.42 and a beta of 0.27. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.10 and a quick ratio of 0.62. The business has a fifty day moving average price of $186.46 and a two-hundred day moving average price of $191.73. Becton, Dickinson and Company has a fifty-two week low of $163.33 and a fifty-two week high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share for the quarter, beating the consensus estimate of $3.40 by $0.28. The firm had revenue of $5.51 billion during the quarter, compared to analysts’ expectations of $5.50 billion. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The company’s quarterly revenue was up 10.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $3.50 EPS. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. As a group, equities analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 30th. Stockholders of record on Monday, September 8th will be issued a dividend of $1.04 per share. The ex-dividend date of this dividend is Monday, September 8th. This represents a $4.16 dividend on an annualized basis and a dividend yield of 2.2%. Becton, Dickinson and Company’s payout ratio is 74.82%.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.